ERBB2 and breast carcinoma: In contrast, our study is based on a large data set (n = 3360), and for each case multiple views of mammography and ultrasound images were used, that are routinely, and virtually everywhere in the world, available for all breast cancer patients; for data labeling, the labeling of molecular subtypes was not only based on IHC results, but used the results of the genetic analysis (SISH, silver-enhanced in situ hybridization) of equivocal/borderline HER2 cases to ensure the correctness of the annotated data.